Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 35 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

25 - 35 of 35

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 35 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05633615

Recruiting

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/17/2024

Locations: Banner University Medical Center - Tucson, Tucson, Arizona +75 locations

Banner University Medical Center - Tucson, Tucson, Arizona

University of Arizona Cancer Center-North Campus, Tucson, Arizona

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Highlands Oncology Group - Rogers, Rogers, Arkansas

Highlands Oncology Group, Springdale, Arkansas

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

UCSF Medical Center-Parnassus, San Francisco, California

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Emory Saint Joseph's Hospital, Atlanta, Georgia

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Loyola University Medical Center, Maywood, Illinois

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky

UofL Health Medical Center Northeast, Louisville, Kentucky

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Bronson Battle Creek, Battle Creek, Michigan

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan

Weisberg Cancer Treatment Center, Farmington Hills, Michigan

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan

Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

West Michigan Cancer Center, Kalamazoo, Michigan

Ascension Borgess Cancer Center, Kalamazoo, Michigan

Trinity Health Muskegon Hospital, Muskegon, Michigan

Corewell Health Lakeland Hospitals - Niles Hospital, Niles, Michigan

Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan

Corewell Health Reed City Hospital, Reed City, Michigan

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center, Saint Joseph, Michigan

Henry Ford Health Providence Southfield Hospital, Southfield, Michigan

Munson Medical Center, Traverse City, Michigan

University of Michigan Health - West, Wyoming, Michigan

University of New Mexico Cancer Center, Albuquerque, New Mexico

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

NYP/Weill Cornell Medical Center, New York, New York

University of Rochester, Rochester, New York

Wilmot Cancer Institute at Webster, Webster, New York

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Case Western Reserve University, Cleveland, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Providence Newberg Medical Center, Newberg, Oregon

Providence Willamette Falls Medical Center, Oregon City, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

Oregon Health and Science University, Portland, Oregon

Geisinger Medical Center, Danville, Pennsylvania

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania

Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania

Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina

Medical University of South Carolina, Charleston, South Carolina

Prisma Health Cancer Institute - Easley, Easley, South Carolina

Prisma Health Cancer Institute - Butternut, Greenville, South Carolina

Prisma Health Cancer Institute - Faris, Greenville, South Carolina

Prisma Health Cancer Institute - Eastside, Greenville, South Carolina

Prisma Health Cancer Institute - Greer, Greer, South Carolina

Prisma Health Cancer Institute - Seneca, Seneca, South Carolina

Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee

University of Vermont Medical Center, Burlington, Vermont

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Froedtert and MCW Moorland Reserve Health Center, New Berlin, Wisconsin

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

Learn More ›

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

NCT04981795

Recruiting

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/05/2024

Locations: Alabama Oncology, Birmingham, Alabama +24 locations

Alabama Oncology, Birmingham, Alabama

Clearview Cancer Institute, Huntsville, Alabama

University of California, Irvine Medical Center, Orange, California

McFarland Clinic P.C., Ames, Iowa

Mission Cancer and Blood, Des Moines, Iowa

Tulane Cancer Center, New Orleans, Louisiana

American Oncology Partners of Maryland PA, Bethesda, Maryland

University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor, Michigan

Henry Ford Health System, Detroit, Michigan

Morristown Medical Center, Morristown, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Westchester Medical Center, Hawthorne, New York

Levine Cancer Institute, Charlotte, North Carolina

VA Medical Center - Durham, Durham, North Carolina

Leo Jenkins Cancer Center/ECU School of Medicine, Greenville, North Carolina

Mercy Medical Center, Canton, Ohio

Ohio Health Marion Area Physicians, Marion, Ohio

Tri County Hematology & Oncology Associates, Inc, Massillon, Ohio

Integris Cancer Institute of Oklahoma, Oklahoma City, Oklahoma

Thomas Jefferson University, Philadelphia, Pennsylvania

Lankenau Medical Center, Wynnewood, Pennsylvania

University of Texas MD Anderson Cancer Center, Houston, Texas

UW Medicine, Seattle, Washington

Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington

Froedtert & Medical College Clinics, Milwaukee, Wisconsin

Conditions: Diffuse Large B-cell Lymphoma

Learn More ›

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

NCT04978584

Recruiting

This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasitamab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide,... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/04/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

NCT05896163

Recruiting

The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking adult participants who: * Have histologically confirmed diagnosis of DLBCL * Have received at least two first lines of treatment for NHL. * Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. Everyone in this study will receive all three medicines at the study site by intravenous (IV) infusion which is given directly into a vein. The two study medicines (maplirpacept \[PF-07901801\] and glofitamab) will be given in 21-day cycles. At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. The combination of maplirpacept (PF-07901801) with glofitamab full dose will be administered for the first time at Cycle 1 Day 1. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every three weeks. Glofitamab will be given every 3 weeks for approximately 9 months. Thereafter participants will continue to receive maplirpacept alone. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. The study will compare the experiences of people receiving different doses of maplirpacept (PF-07901801). This will help to determine what dose is safe and effective when given with the other 2 study medicines. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/22/2024

Locations: The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas +22 locations

The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas

The University of Kansas Clinical Research Center, Fairway, Kansas

The University of Kansas Hospital, Kansas City, Kansas

University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas

Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

Barnes-Jewish Hospital Parkview Tower, Saint Louis, Missouri

Barnes-Jewish Hospital, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Swedish Cancer Institute, Seattle, Washington

Swedish Medical Center, Seattle, Washington

Princess Alexandra Hospital, Brisbane, Queensland

St Vincent's Hospital Melbourne, Fitzroy, Victoria

Sheba Medical Center, Ramat Gan, Hamerkaz

Rambam Health Care Campus, Haifa, Hatsafon

Hadassah Medical Center, Jerusalem, Yerushalayim

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi

Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka

National Hospital Organization Kyushu Cancer Center, Fukuoka, Not set

China Medical University Hospital, Taichung, Not set

National Taiwan University Hospital, Taipei, Not set

Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

NCT05455697

Recruiting

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/18/2024

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma

Learn More ›

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251

Recruiting

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2024

Locations: UACC Arizona, Tucson, Arizona +175 locations

UACC Arizona, Tucson, Arizona

University of California San Francisco, San Francisco, California

University of California Los Angeles (UCLA), Santa Monica, California

Boca Raton Cancer Research Medical Center, Plantation, Florida

University of Chicago, Chicago, Illinois

Robert H. Lurie Comprehensive Cancer Center/Northwestern University, Chicago, Illinois

Norton Cancer Institute, Louisville, Kentucky

Dana Farber Cancer Institute, Boston, Massachusetts

Tufts Medical Center, Boston, Massachusetts

Lahey Clinic, Burlington, Massachusetts

University of Massachusetts Medical School, Worcester, Massachusetts

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Clinical Research Alliance, Lake Success, New York

New York Presbyterian Hospital/ Cornell Medical College, New York, New York

Stony Brook University Hospital, Stony Brook, New York

Gabrail Cancer Center, Canton, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

University Hospitals Seidman Cancer Center, Cleveland, Ohio

University of Oklahoma, Oklahoma City, Oklahoma

Greenville Hospital System, Greenville, South Carolina

MD Anderson, Houston, Texas

Swedish Cancer Institute, Seattle, Washington

Virginia Mason Hospital & Medical Center, Seattle, Washington

St. Vincent's Hospital Sydney, Darlinghurst, New South Wales

Liverpool Hospital, Ingham Institute of Medical Research, Liverpool, New South Wales

Calvary Mater Newcastle Hospital, Waratah, New South Wales

Icon Cancer Care, South Brisbane, Queensland

Royal Adelaide Hospital, Adelaide, South Australia

Ashford Cancer Centre, Kurralta Park, South Australia

Monash Medical Centre, Clayton, Victoria

Epworth Hospital, East Melbourne, Victoria

St. Vincent's Melbourne, Fitzroy, Victoria

The Alfred Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Medical University of Graz, Graz, Not set

Medizinische Universität Innsbruck für Innere Medizin, Innsbruck, Not set

LKH Leoben Department for Haemato-Oncology, Leoben, Not set

Akh Linz Innere Med III - Zentrum für Hämatologie und med. Onkologie, Linz, Not set

Krankenhaus Barmherzigen Schwestern Linz, Linz, Not set

Krankenhaus der Elisabethinen Linz GmbH, Linz, Not set

Uni. Klinik für Innere Medizin III Universitätsklinikum der PMU LKH Salzburg, Salzburg, Not set

Medical University of Vienna (MUW) Department of Medicine I, Vienna, Not set

Univ. General Hospital Hietzing, Vienna, Not set

Ziekenhuis Netwerk Antwerpen, Antwerpen, Not set

AZ Sint-Jan, Bruges, Not set

Institut Jules Bordet, Brussels, Not set

Cliniques Universitaires Saint-Luc, Brussels, Not set

UZ Gent, Gent, Not set

CH Jolimont, La Louviere, Not set

AZ Delta, Roeselare, Not set

H-Hartziekenhuis Roeselare-Menen, Roeselare, Not set

University Hospital for Active Treatment Dr. Georgi Stranski, Pleven, Not set

University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Not set

Specialized Hospital for Active Treatment of Haematological Diseases EAD, Sofia, Not set

Princess Margaret Cancer Centre, Toronto, Ontario

Sir Mortimer B Davis Jewish General Hospital/McGill University, Montreal, Quebec

CHU Lyon Sud, Pierre-Bénite, Lyon

Centre Hospitalier Universitaire Henri Mondor, Créteil, Not set

Unite Hemopathies Lymphoides Chu Henri Mondor, Créteil, Not set

Chu Dijon-Bourgogne - Hematologie Clinique, Dijon, Not set

Hospitalier de la Rochelle-Ré-Aunis, La Rochelle, Not set

CHRU de Lille - Hopital Claude-Huriez, Lille, Not set

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, Not set

CHU Montpellier, Montpellier, Not set

Hostpial Saint Louis - CIRCO (Centre d'Investigations et de Recherche Clinique en Oncologie), Paris, Not set

Hôpital Necker Service d'Hématologie Adult, Paris, Not set

Pitié-Salpêtrière Hospital, Paris, Not set

Centre Henri Becquerel, Rouen, Not set

Uniklinik Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Not set

HELIOS Klinikum Bad Saarow, Bad Saarow, Not set

Charite Universitatsmedizin Berlin (Benjamin Franklin Campus), Berlin, Not set

Charite Universitatsmedizin Berlin (Virchow Campus), Berlin, Not set

Ev. Diakonie-Krankenhaus gGmbH, Bremen, Not set

Gemeinschaftspraxis Haematologie and Onkologie-Dresden, Dresden, Not set

Martin-Luther-University Halle-Wittenberg Department of Oncology, Halle, Not set

Medizinische Hochschule, Hannover, Not set

Universität Heidelberg Medizinische Klinik V Hämatologie, Onkologie und Rheumatologie, Heidelberg, Not set

Klinikum Kempten Klinik für Innere Medizin III - Hämatologie, Onkologie und Palliativmedizin, Koln, Not set

Klinikum Leverkusen, Leverkusen, Not set

Klinikum Ludwigshafen, Ludwigshafen, Not set

Rotkreuzklinikum München, Muenchen, Not set

Klinikum Nürnberg Nord, Nuernberg, Not set

Haematology Department and HCT Unit G.Papanicolaou Hospital, Exochi, Thessaloniki

Hematology Clinic,General Hospital of Athens,G. Gennimatos, Athens, Not set

National & Kapodistrian University of Athens, Laiko General Hospital, Athens, Not set

Hematology Department Laiko General Hospital, Athens, Not set

Second Depth of Internal Medicine, Attiko University Hospital, Athens, Not set

National & Kapodistrian University of Athens, Attiko University Hospital, Chaidari, Not set

Department of clinical hematology ,university hospital Ioannina, Ioánnina, Not set

University of Patras Medical School, Patras, Not set

Semmelweis Egyetem Általános Orvosi Kar, Budapest, Not set

Országos Onkológiai Intézet "A" Belgyógyászati Onkológiai Osztály, Budapest, Not set

Semmelweis University Department of Medicine and Oncology, Budapest, Not set

Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Not set

Pécsi Tudományegyetem, ÁOK, I. számú Belgyógyászati Klinika, Pécs, Not set

Veszprém Megyei Csolnoky Ferenc Kórház, Veszprém, Not set

CSolnoky ferenc Hospital, Veszprém, Not set

Regional Cancer Centre, IGIMS, Patna, Bihar

SRM Institutes for Medical Science, Vadapalani, Chennai

Rajiv Gandhi Cancer Hospital, New Delhi, Delhi

Regional Cancer Centre, Thiruvananthapuram, Kerala

Prince Aly Khan Hospital, Mumbai, Maharashtra

Jaslok Hospital and Research Centre, Mumbai, Maharashtra

Deenanath Mangeshkar Hospital, Pune, Maharashtra

Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha

Dayanand Medical College and Hospital, Ludhiāna, Punjab

Cancer Institute (WIA), Chennai, Tamil Nadu

Saveetha Medical College Hospital, Chennai, Tamil Nadu

G. Kuppu Swamy Naidu Hospital, Coimbatore, Tamil Nadu

Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu

King George's Medical University (KGMU), Lucknow, Uttar Pradesh

Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal

Netaji Subhas Chandra Bose Cancer Research Hospital, Kolkata, West Bengal

TATA Memorial Centre, Kolkata, West Bengal

Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal

IRCH, All India Institute of Medical Sciences, Delhi, Not set

Dr. B.R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences, New Delhi, Not set

Hematology-Soroka, Beer Sheva, Not set

Rambam Healthcare Campus, Haifa, Not set

Wolfson MC, Holon, Not set

Hadassah Medical Center, Jerusalem, Not set

Rabin Medical Center, Petach Tikva, Not set

Assuta Medical Center, Tel Aviv, Not set

TLV Sorasky Medical Center, Tel Aviv, Not set

Sheba Medical Center, Tel Hashomer, Not set

Instituto di Ematologia Seragnoli Pad 8 Universita di Bologna, Bologna, Not set

SODc Ematologica ,AOU Careggi, Florence, Not set

AOU Maggiore della Carità SCDU Ematologia, Florence, Not set

Hematology-Oncology & Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Not set

SCDU Ematologia, Division of Hematology, Dept. of Translational Medicine, Universita del Piemonte Orientale, Novara, Not set

Fondazione Policlinico Universitario A. Gemelli, Rome, Not set

Azienda Ospedaliero-Universitaria Senese, Siena, Not set

Città della Salute e della Scienza di Torino, Torino, Not set

VUMc (Vrije Universiteit Amsterdam), Amsterdam, Not set

LUMC (leidse universitair medisch centrum), Leiden, Not set

North Shore Hospital, Auckland, Not set

Christchurch Hospital, Christchurch, Not set

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza, Wrocław, Radeckiego

Szpitale Wojewódzkie w Gdyni, Gdyńskie Centrum onkologii, Gdynia, Not set

MCM (Małopolskie Centrum Medyczne), Krakow, Not set

Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica, Not set

Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Not set

Hematology Department St John's Cancer Centre, Lublin, Not set

Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa, Olsztyn, Not set

Instytut Hematologii i Transfuzjologii, Warszawa, Not set

Centrum Onkologii- Insytut Im. Marii Skłodowskiej-Curie Klinika Nowotworow Ukladu Chlonnego, Warszawa, Not set

Maria Sklodowska Curie National Research Institute, Warszawa, Not set

Memorial Provincial Specialist Hospital in Lodz, Łódź, Not set

Institut za onkologiju i radiologiju Srbije, Belgrade, Not set

Klinicko Bolnick Centar Zemun Odeljenje hematologije, Belgrade, Not set

Klinički centar Srbije Klinika za hematologiju, Belgrade, Not set

Kliničko bolnički centar Zvezdara, Belgrade, Not set

Klinički centar Niš Klinika za hematologiju, Nis, Not set

Institut za onkologiju Vojvodine, Sremska Kamenica, Not set

Hospitla Universitari Germans Trias i Pujol - ICO, Badalona, Not set

Hospital University Vall d'Hebron, Barcelona, Not set

Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital de Son Llàtzer, Palma de Mallorca, Not set

Clínica Universidad De Navarra, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Gloucestershire Royal Hospital, Gloucester, Gloucestershire

Southampton University Hospital, Southampton, Hampshire

Royal Marsden Hospital, Sutton, London

Northwick Park Hospital, Harrow, Middlesex

Leeds Teaching Hospitals NHS Trust, Leeds, Yorkshire

Addenbrooke's Hospital Cambridge, Cambridge, Not set

Royal Liverpool University Hospital, Liverpool, Not set

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set

King's College Hospital, London, Not set

Princess Royal University Hospital (PRUH), London, Not set

Guy's and St Thomas' NHS Foundation Trust, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Oxford University Hospitals NHS Trust Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, Not set

Derriford Hospital, Plymouth, Not set

Conditions: Diffuse Large B-cell Lymphoma

Learn More ›

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

NCT05660395

Recruiting

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment.

Gender:

All

Ages:

18 years and above

Trial Updated:

06/20/2024

Locations: The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California +13 locations

Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma

Learn More ›

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409

Recruiting

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/03/2024

Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +4 locations

Conditions: Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Nasal Type Extranodal NK/T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Anaplastic Large Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Small Lymphocytic Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma

Learn More ›

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

NCT04479267

Recruiting

This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma. Polatuzumab vedotin is a monoclonal antibody that works by binding with cancer cells and releasing another chemotherapy drug, called monomethyl auristatin E, into the cell causing the cancer cells to die or stop growing. Chemotherapy drugs, such as rituximab, cyclophosphamide... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

03/19/2024

Locations: Karmanos Cancer Institute, Detroit, Michigan

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma

Learn More ›

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT03147885

Recruiting

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lym... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

03/19/2024

Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma

Learn More ›

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

NCT02393157

Recruiting

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Gender:

All

Ages:

Between 3 years and 31 years

Trial Updated:

10/24/2023

Locations: New York Medical College, Valhalla, New York

Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III

Learn More ›

25 - 35 of 35